Memantine Tablet
Product Images NDC 60687-184

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Memantine (NDC 60687-184). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 mg Blister

Memantine Hydrochloride Tablet, USP 10 mg label sheet from American Health Packaging. The sheet includes multiple identical labels, each showing the product name, strength (10 mg), formatted for oral tablet use, with placeholders for lot number, expiration date, and barcode. American Health Packaging, Columbus, Ohio, is identified as the labeler.*

FDA Label Image

10 mg Carton

Memantine Hydrochloride 10 mg oral tablets packaging label from American Health Packaging. The label shows quantity of 60 tablets (6 blister packs of 10 each) with NDC 60687-184-57. Includes dosing information, storage conditions, and a patient information dispensing instruction. The label states Rx only and includes manufacturer details and barcode.*

FDA Label Image

5 mg Blister

Label sheet for Memantine Hydrochloride tablets, USP, 5 mg strength, showing multiple individual labels. Each label includes the product name, strength, bar code, lot number, expiry date fields, and American Health Packaging as the labeler, with a Columbus, Ohio address.*

FDA Label Image

5 mg Carton

Memantine Hydrochloride 5 mg oral tablets label showing 60 tablets (6 bottles of 10 tablets each) manufactured by American Health Packaging. The label includes NDC 60687-173-57, dispensing instructions, storage conditions, and prescription only designation.*

FDA Label Image

883dccf8 44b2 5f82 E053 2995a90a12dd

Memantine 10 mg oral tablet imprinted with 'RDY' on one side and '596' on the other. The tablet is oblong and peach-colored. Labeler is American Health Packaging.*

FDA Label Image

883dccf8 44b3 5f82 E053 2995a90a12dd

Memantine 10 mg oral tablet, white, oblong with the imprint 'RDY 597' on one side and '597' on the other. The image shows the tablet's shape, color, and identifying imprint as provided by American Health Packaging.*

FDA Label Image

Memantine HCl Structural Formula (Image 01 01)

Chemical structure of Memantine hydrochloride shown as a molecular diagram with labeled amine group (NH2), hydrochloride (HCl), and methyl groups (CH3). The structure depicts a cage-like cycloalkane framework characteristic of Memantine.*

FDA Label Image

Figure 1: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 28 Weeks Of Treatment. (Image 02 01)

A line graph comparing mean change from baseline in ADCS-ADL scores over 28 weeks of treatment between placebo and Memantine HCl groups. The x-axis represents weeks of treatment (0, 4, 12, 28), and the y-axis shows mean change with standard error bars. The graph indicates clinical improvement and decline thresholds, with the Memantine HCl group showing less decline than placebo over time.*

FDA Label Image

Figure 2: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Image 03 01)

A cumulative percentage of patients line graph comparing Memantine HCl and placebo on ADCS-ADL change from baseline. The x-axis measures ADCS-ADL change, and the y-axis shows the cumulative percentage of patients, with Memantine HCl represented by circles and placebo by squares.*

FDA Label Image

Figure 3: Time Course Of The Change From Baseline In Sib Score For Patients Completing 28 Weeks Of Treatment. (Image 04 01)

A line graph showing mean (± SEM) change from baseline in SIB Score over 28 weeks of treatment, comparing Placebo and Memantine HCl groups. The graph includes error bars, two reference lines labeled Clinical Improvement and Clinical Decline, and plots the changes at 0, 4, 12, and 28 weeks for both groups.*

FDA Label Image

Figure 4: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Image 05 01)

A cumulative percentage of patients graph comparing Placebo and Memantine HCl groups with SIB (Severe Impairment Battery) Change from Baseline on the horizontal axis and cumulative percentage on the vertical axis. The graph shows two plotted lines representing the treatment groups' improvement or change over the study period.*

FDA Label Image

Figure 5: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 24 Weeks Of Treatment. (Image 06 01)

A line graph depicting the mean change from baseline in ADCS-ADL score over 24 weeks of treatment. The x-axis shows weeks of treatment from 0 to 24, and the y-axis shows mean change from baseline ranging from -3.5 to 1. Two treatment groups are compared: Placebo/Donepezil (square markers) showing a decline, and Memantine HCl/Donepezil (circle markers) showing stable scores. Error bars indicate variability for each data point. Clinical improvement and decline are marked as reference lines on the y-axis.*

FDA Label Image

Figure 6: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Image 07 01)

A cumulative percentage of patients graph comparing ADCS-ADL change from baseline between two groups: Placebo/Donepezil and Memantine HCl/Donepezil. The x-axis shows negative values of ADCS-ADL change, while the y-axis indicates cumulative percentage of patients from 0 to 100%. Data show two lines, with Memantine HCl/Donepezil patients generally having a higher cumulative percentage at more negative ADCS-ADL changes.*

FDA Label Image

Figure 7: Time Course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Image 08 01)

A line graph comparing the mean change from baseline in SIB score over 24 weeks of treatment between Placebo/Donepezil and Memantine HCl/Donepezil groups. The x-axis represents weeks of treatment, and the y-axis shows mean change with error bars. The graph indicates clinical improvement and clinical decline thresholds.*

FDA Label Image

Figure 8: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Image 09 01)

A cumulative percentage of patients graph showing SIB (Severe Impairment Battery) change from baseline, comparing Memantine HCl/Donepezil and Placebo/Donepezil groups. The x-axis represents SIB change from baseline, ranging from 20 to -30, and the y-axis represents the cumulative percentage of patients from 0% to 100%. Memantine HCl/Donepezil shows a higher cumulative percentage at more negative SIB changes, indicating greater change compared to Placebo/Donepezil.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.